Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea

Fineline Cube Apr 7, 2025

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) has secured clinical trial approval from China’s National...

Company Deals

Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline

Fineline Cube Apr 7, 2025

China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial...

Company Drug

Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment

Fineline Cube Apr 7, 2025

Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from China’s National...

Company Medical Device

Peijia Medical’s ReachTactile Robot Assists First Human TAVR Trial

Fineline Cube Apr 7, 2025

China’s Peijia Medical Ltd (HKG: 9996) has announced the successful treatment of the first patient...

Company Drug

Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer

Fineline Cube Apr 7, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that they have received approval...

Company Drug

Sino Biopharmaceutical’s TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies

Fineline Cube Apr 7, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the National...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors

Fineline Cube Apr 7, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical trial...

Company Drug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases

Fineline Cube Apr 7, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received Orphan Drug Designation (ODD) from...

Company Drug

Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial

Fineline Cube Apr 7, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG:...

Company Drug

Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt

Fineline Cube Apr 7, 2025

The European Medicines Agency (EMA) may lift the temporary hold on certain Phase III studies...

Company Drug

Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor

Fineline Cube Apr 7, 2025

German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the...

Company Deals

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform

Fineline Cube Apr 7, 2025

South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement...

Company

BeiGene Halts Ociperlimab Clinical Program for Lung Cancer

Fineline Cube Apr 7, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as...

Company Deals

Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology

Fineline Cube Apr 7, 2025

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...

Company Medical Device

MicroPort Endovascular’s Talos Stent Approved in Brazil for Aortic Dissection

Fineline Cube Apr 7, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Company Drug

Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA

Fineline Cube Apr 7, 2025

China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...

Company Deals

Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies

Fineline Cube Apr 3, 2025

US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...

Company Deals Medical Device

Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development

Fineline Cube Apr 3, 2025

Beijing Yuewei Medical Technology Co., Ltd, a medical device company specializing in coronary heart disease,...

Company

Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals

Fineline Cube Apr 3, 2025

Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...

Company Deals

GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices

Fineline Cube Apr 3, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has entered...

Posts pagination

1 … 126 127 128 … 609

Recent updates

  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.